Literature DB >> 2996951

The effects of spironolactone on adrenal steroidogenesis in hirsute women.

P Serafini, R A Lobo.   

Abstract

The effect of spironolactone on adrenal androgen and cortisol production was studied in six hirsute women. Hirsute women were evaluated before and 1 month after receiving 200 mg of spironolactone daily. Basal levels of serum androgens, 17-hydroxyprogesterone (17-OHP), cortisol (F), corticosteroid-binding globulin, and plasma adrenocorticotropic hormone (ACTH) were normal and did not change with therapy. The delta maximum (delta max) responses after dexamethasone suppression and ACTH administration of dehydroepiandrosterone (DHEA), androstenedione (delta 4A), 17-hydroxypregnenolone, and 17-OHP were similar in hirsute women and ovulatory control subjects. After spironolactone administration, the delta max DHEA response was unchanged, whereas the delta max delta 4A response was decreased (P less than 0.05). The delta max ratios of DHEA/delta 4A and 17-OHP/delta 4A were significantly increased after spironolactone in hirsute women, which suggested inhibitions of 3 beta-ol-dehydrogenase-isomerase and delta 4 17,20 desmolase activities. A significant reduction in delta max F occurred after spironolactone administration (P less than 0.05). Although baseline 11-desoxycortisol (S) and the plasma S/ACTH ratio were unaltered, the delta max S/F ratio increased after treatment (P less than 0.01), suggesting an inhibition of 11 beta-hydroxylase activity. Inhibition of adrenal androgen production occurs with spironolactone, but only serum levels of delta 4A are decreased, whereas DHEA and its sulfate (DHEA-S) levels remain unchanged.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996951     DOI: 10.1016/s0015-0282(16)48972-7

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

Review 1.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

Review 2.  A risk-benefit assessment of pharmacological therapies for hirsutism.

Authors:  E Carmina
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism.

Authors:  Manouchehr Nakhjavani; Sepehr Hamidi; Alireza Esteghamati; Mehrshad Abbasi; Simindokht Nosratian-Jahromi; Parvin Pasalar
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.